Business Wire

Boston BioProducts Receives ISO 13485:2016 Quality Certification

Share

Boston BioProducts, a longstanding manufacturer of fundamental reagents for the life sciences, today announced that its quality management system (QMS) has achieved ISO 13485:2016 certification from TÜV SÜD America for the medical device manufacturing and supply of buffers, solutions, media, and reagents serving research, diagnostics, and therapeutics applications. Achieving this certification signifies Boston BioProducts’ commitment to high-quality standards across the entire reagent manufacturing process.

ISO 13485:2016 is considered the industry standard for QMS systems designed for medical devices and related services. It sets a robust and reproducible framework for the design, development, and manufacturing of products that meets customer and regulatory requirements. The International Organization for Standardization (ISO) is a global, independent publisher of standards governing the safety, reliability, and quality of manufactured products. TÜV SÜD America is among the most respected and accomplished certification bodies in the market serving thousands of registrations worldwide.

“This major company milestone further supports Boston BioProducts’ path to becoming a premier partner for contract reagent development and manufacturing across research, diagnostics, and therapeutics”, said Neil Sharma, General Manager of Boston BioProducts. “Scientists, assay developers, and manufacturing engineers can rely on a single source for the customization, testing, and supply of their process-critical buffers, solutions, and media reagents whether starting from innovation to publication, RUO to IVD, or preclinical to GMP.”

With the ISO 13485:2016 certification, Boston BioProducts is better positioned to support a range of growing regulated applications such as in vitro diagnostics, clinical trial assays , and cell and gene therapy manufacturing. This elevated quality management system complements the company’s flexible custom reagent manufacturing and rapid product delivery.

About Boston BioProducts

For nearly 30 years, Boston BioProducts (BBP) has manufactured and supplied fundamental reagents (buffers, solutions, media, and more) to researchers, diagnostic and technology platforms, and drug developers worldwide. With its custom reagent manufacturing services, BBP becomes an extension of your lab with flexible parameters to design the ideal research and manufacturing tools. Its mission is to increase the reproducibility of product- and process-critical reagents that keep your science consistent and moving forward. For more information, please visit www.bostonbioproducts.com and follow us on LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Boston BioProducts Marketing
marketing@bostonbioproducts.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 21:00:00 EET | Press release

Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus

ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 20:30:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 8, 2026, from 8:57- 9:07 a.m. PST. HERIZON-GEA-01 met the dual primary endpoint of progression-free survival (PFS), demonstrating statistically significant and clinically meaningful improvements in both experimental arms compared to the control arm. The addition of TEVIMBRA to ZIIHERA and chemotherapy also sho

Siemens and NVIDIA Expand Partnership to Build the Industrial AI Operating System6.1.2026 19:07:00 EET | Press release

CES 2026 - Siemens and NVIDIA today announced a significant expansion of their strategic partnership to bring artificial intelligence into the real world. Together, the companies aim to develop industrial and physical AI solutions that will bring AI-driven innovation to every industry and industrial workflow, as well as accelerate each others’ operations. To support development, NVIDIA will provide AI infrastructure, simulation libraries, models, frameworks and blueprints, while Siemens will commit hundreds of industrial AI experts and leading hardware and software. “Together, we are building the Industrial AI operating system – redefining how the physical world is designed, built, and run - to scale AI and create real-world impact,” said Roland Busch, President and CEO of Siemens AG. “By combining NVIDIA’s leadership in accelerated computing and AI platforms with Siemens’ leading hardware, software, industrial AI and data, we’re empowering customers to develop products faster with the

Quectel Debuts Innovative SRG091X and SRG093X NXP i.MX Based Series Modules with Wi-Fi 6, Redefining Entry-level Processing for Next-generation IoT Applications6.1.2026 19:00:00 EET | Press release

Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today unveiled its SRG091X and SRG093X series modules at CES in Las Vegas, delivering integrated CPU, memory and wireless connectivity built around the NXP® Semiconductors i.MX 9 series of applications processors. This new generation of modules is engineered for industrial environments demanding high levels of automation, as well as consumer applications that require high data throughput and advanced multimedia capabilities. By integrating memory and wireless functionality into a single solution, the modules simplify OEM design, accelerate time to market, and reduce development effort for IoT manufacturers worldwide. These modules are well suited for a wide range of applications, including industrial HMIs, gateways, scanners, printers, energy meters, EV charging stations, smart speakers, POS systems, smart doorbells, smart locks, and many other connected devices. “The SRG091X and SRG093X series modules are designed

Siemens Unveils Technologies to Accelerate the Industrial AI Revolution at CES 20266.1.2026 19:00:00 EET | Press release

At CES 2026, Siemens’ keynote marked a new era of technology for industry and infrastructure, showcasing how customers and partners are harnessing artificial intelligence to transform their businesses. With AI-enabled technologies, deep domain expertise, and trusted partnerships, Siemens is converting this technological leap into measurable benefits for customers, partners, and society. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106633962/en/ Roland Busch, Chief Executive Officer and President of Siemens AG, delivering the keynote address at CES. “Just as electricity once revolutionized the world, industry is shifting toward elements where AI powers products, factories, buildings, grids and transportation. Industrial AI is no longer a feature; it’s a force that will reshape the next century. Siemens is delivering AI-native capabilities, intelligence embedded end-to-end across design, engineering and operations, to hel

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye